Education
About Us
Working with TipRanks
Follow Us
PepGen Inc. (PEPG)
NASDAQ:PEPG
PEPG Analyst Ratings
Moderate Buy
3 Buy
0 Hold
1 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
PEPG Stock 12 Month Forecast
Average Price Target
$7.00
▲(442.64% Upside)
| Highest Price Target$10.00 | Average Price Target$7.00 | Lowest Price Target$1.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Bank of America Securities
$1
Sell
-22.48%
Downside
Reiterated
08/14/25
H.C. Wainwright
$8
Buy
520.16%
Upside
Reiterated
08/11/25
PepGen Inc.'s Promising Clinical Developments and Strategic Advancements Earn a Buy RatingValuation and Risks. Our price target of $8 is based on an equally weighted composite of: (a) $13/share, as a 18x multiple of taxed and diluted 2034 EPS of $2/share discounted back to and (b) an NPV discounted cash flow between 2025-2034 of $3/share, with a discount rate of 11% and growth rate of 2%. These assumptions are in line with the expected P/E multiple and discount rates of an early developmental-stage biopharmaceutical company.
Stifel Nicolaus
$9
Buy
597.67%
Upside
Reiterated
08/08/25
Leerink Partners
$10
Buy
675.19%
Upside
Reiterated
08/07/25
Analysts Offer Insights on Healthcare Companies: PepGen Inc. (NASDAQ: PEPG), Cullinan Management (NASDAQ: CGEM) and aTyr Pharma (NASDAQ: ATYR)We saw 12.3% and 29.1% splicing correction for 5 mg/kg and 10 mg/kg, respectively, that was accompanied by some early trends in 10-meter walk/run test (10MWRT) and myotonia measured by video hand opening time (vHOT), already approaching levels that were seen with 6 and 12 months of repeat dosing with the assets from RNA (OP) and DYN (Not Rated), which we think bodes well for repeat dosing. Importantly, PEPG's approach in DM1 is differentiated from RNA and DYN, which we think has the potential to drive greater efficacy over time. PGN-EDODM1 is a peptide-conjugated ASO designed to bind only to mutant DMPK mRNA transcripts to block the toxic CUG repeat, thereby reducing the toxic nuclear foci while leaving wild-type DMPK intact, while RNA's del-desiran and DYN's DYNE-101 both target all DMPK for degradation (see here and here).
TR | OpenAI - 4o
―
Sell
―
Downgraded
05/03/25
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Bank of America Securities
$1
Sell
-22.48%
Downside
Reiterated
08/14/25
H.C. Wainwright
$8
Buy
520.16%
Upside
Reiterated
08/11/25
PepGen Inc.'s Promising Clinical Developments and Strategic Advancements Earn a Buy RatingValuation and Risks. Our price target of $8 is based on an equally weighted composite of: (a) $13/share, as a 18x multiple of taxed and diluted 2034 EPS of $2/share discounted back to and (b) an NPV discounted cash flow between 2025-2034 of $3/share, with a discount rate of 11% and growth rate of 2%. These assumptions are in line with the expected P/E multiple and discount rates of an early developmental-stage biopharmaceutical company.
Stifel Nicolaus
$9
Buy
597.67%
Upside
Reiterated
08/08/25
Leerink Partners
$10
Buy
675.19%
Upside
Reiterated
08/07/25
Analysts Offer Insights on Healthcare Companies: PepGen Inc. (NASDAQ: PEPG), Cullinan Management (NASDAQ: CGEM) and aTyr Pharma (NASDAQ: ATYR)We saw 12.3% and 29.1% splicing correction for 5 mg/kg and 10 mg/kg, respectively, that was accompanied by some early trends in 10-meter walk/run test (10MWRT) and myotonia measured by video hand opening time (vHOT), already approaching levels that were seen with 6 and 12 months of repeat dosing with the assets from RNA (OP) and DYN (Not Rated), which we think bodes well for repeat dosing. Importantly, PEPG's approach in DM1 is differentiated from RNA and DYN, which we think has the potential to drive greater efficacy over time. PGN-EDODM1 is a peptide-conjugated ASO designed to bind only to mutant DMPK mRNA transcripts to block the toxic CUG repeat, thereby reducing the toxic nuclear foci while leaving wild-type DMPK intact, while RNA's del-desiran and DYN's DYNE-101 both target all DMPK for degradation (see here and here).
TR | OpenAI - 4o
―
Sell
―
Downgraded
05/03/25
Best Analysts Covering PepGen Inc.
1 Month
xxx
Success Rate
8/11 ratings generated profit
Average Return
+15.93%
reiterated a xxx
rating 3 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 72.73% of your transactions generating a profit, with an average return of +15.93% per trade.
3 Months
xxx
Success Rate
6/11 ratings generated profit
Average Return
+1.91%
reiterated a xxx
rating 3 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 54.55% of your transactions generating a profit, with an average return of +1.91% per trade.
1 Year
Success Rate
9/11 ratings generated profit
Average Return
+26.95%
reiterated a sell rating 3 days ago
Copying Tazeen Ahmad's trades and holding each position for 1 Year would result in 81.82% of your transactions generating a profit, with an average return of +26.95% per trade.
2 Years
xxx
Success Rate
7/11 ratings generated profit
Average Return
+23.75%
reiterated a xxx
rating 3 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 63.64% of your transactions generating a profit, with an average return of +23.75% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
PEPG Analyst Recommendation Trends
Rating
Feb 25
Mar 25
Apr 25
May 25
Aug 25
Strong Buy
5
5
3
5
8
Buy
2
1
0
0
0
Hold
3
3
1
1
1
Sell
4
4
5
3
3
Strong Sell
0
0
0
0
0
total
14
13
9
9
12
Each month's total comprises the sum of three months' worth of ratings.
PEPG Financial Forecast
PEPG Stock Forecast FAQ
What is PEPG’s average 12-month price target, according to analysts?
Based on analyst ratings, PepGen Inc.’s 12-month average price target is 7.00.
What is PEPG’s upside potential, based on the analysts’ average price target?
PepGen Inc. has 442.64% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is PEPG a Buy, Sell or Hold?
PepGen Inc. has a consensus rating of Moderate Buy which is based on 3 buy ratings, 0 hold ratings and 1 sell ratings.
What is PepGen Inc.’s price target?
The average price target for PepGen Inc. is 7.00. This is based on 4 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $10.00 ,the lowest forecast is $1.00. The average price target represents 442.64% Increase from the current price of $1.29.
The highest analyst price target is $10.00 ,the lowest forecast is $1.00. The average price target represents 442.64% Increase from the current price of $1.29.
What do analysts say about PepGen Inc.?
PepGen Inc.’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 4 Wall Streets Analysts.
How can I buy shares of PEPG?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.